Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19.
Med Hypotheses
; 150: 110564, 2021 May.
Article
in English
| MEDLINE | ID: covidwho-1144869
ABSTRACT
We summarize the role of endothelin as a potent vasoconstrictor, pro-inflammatory, pro-oxidative agent in the pathophysiologic effects and end-organ dysfunction of coronavirus disease 2019 (COVID-19). Endotheliitis is an under-recognized pathophysiologic process that causes various types of dysfunction in end organs, including heart, lung, kidney, and brain. Endothelin receptor blockers, such as bosentan and sitaxentan, can pave a path ahead in the realm of COVID-19 therapies. These agents have a potential role against COVID-19 and should be studied in research trials to determine their efficacy in treatment of this severe disease.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Endothelium, Vascular
/
Endothelin Receptor Antagonists
/
COVID-19 Drug Treatment
Limits:
Humans
Language:
English
Journal:
Med Hypotheses
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS